Above from left to right: Professors Karl Kieburtz, David Simon and Michael Schwarzschild discuss prioritisation at our recent Linked Clinical Trials meeting.

The Linked Clinical Trials (LCT) committee met again this autumn at the fourth meeting of its kind at the Van Andel Institute's Grand Challenges in Parkinson's symposium. The LCT committee evaluated a proposed 27 potential individual compounds and agreed upon those treatments with the most compelling biochemical evidence to potentially slow, stop, reverse Parkinson's (PD). The committee prioritised: 

These treatments were prioritised above others in regard to their safety and tolerability records, the treatment pathways as well as the strength of the practical and scientific rationale for taking them through to clinical trials in PD.